NASDAQ · PRCT
Healthcare · Medical - Devices
$21.68
Up+$0.95 (+4.58%)
Updated Aug 22, 2026, 11:57 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PRCT closed at $21.68 after 21 trading sessions, up 29.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $20.77 | $22.00 | $20.77 | $21.68 | 821.95K |
| Aug 20, 2026 | $21.87 | $21.90 | $20.69 | $20.73 | 1.29M |
| Aug 19, 2026 | $21.69 | $22.2025 | $21.595 | $21.91 | 635.99K |
| Aug 18, 2026 | $21.10 | $21.88 | $21.10 | $21.32 | 819.53K |
| Aug 17, 2026 | $21.28 | $21.63 | $20.78 | $21.09 | 998.8K |
| Aug 14, 2026 | $22.10 | $22.10 | $21.40 | $21.65 | 751.43K |
| Aug 13, 2026 | $21.25 | $22.80 | $21.16 | $21.95 | 1.24M |
| Aug 12, 2026 | $22.445 | $22.68 | $21.175 | $21.25 | 1.16M |
| Aug 11, 2026 | $21.50 | $22.93 | $21.19 | $22.89 | 1.4M |
| Aug 10, 2026 | $21.18 | $22.22 | $20.83 | $21.71 | 2.02M |
| Aug 7, 2026 | $20.04 | $21.26 | $19.77 | $20.41 | 1.76M |
| Aug 6, 2026 | $18.88 | $20.06 | $17.665 | $20.03 | 2.3M |
| Aug 5, 2026 | $17.46 | $19.62 | $17.12 | $19.34 | 5.46M |
| Aug 4, 2026 | $17.57 | $18.49 | $17.552 | $18.28 | 3.73M |
| Aug 3, 2026 | $18.87 | $19.17 | $17.84 | $18.38 | 2.9M |
| Jul 31, 2026 | $18.01 | $18.67 | $17.71 | $18.62 | 1.18M |
| Jul 30, 2026 | $17.85 | $18.09 | $17.44 | $18.00 | 1.21M |
| Jul 29, 2026 | $17.90 | $18.33 | $17.74 | $17.88 | 991.91K |
| Jul 28, 2026 | $17.27 | $18.32 | $17.27 | $18.08 | 1.58M |
| Jul 27, 2026 | $16.97 | $18.14 | $16.86 | $17.69 | 1.34M |
| Jul 24, 2026 | $17.58 | $17.81 | $16.665 | $16.69 | 1.89M |
The latest Smart Investors Daily articles mentioning PRCT.
PRCT research
Company profile and research snapshot.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | William Blair | Market Perform | — |
| Aug 5, 2026 | Piper Sandler | Overweight | — |
| Aug 5, 2026 | TD Cowen | Buy | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Jul 6, 2026 | Truist Securities | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Mar 30, 2026
PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.
SeekingAlpha · Mar 6, 2026
PROCEPT BioRobotics Corporation (PRCT) TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM ESTCompany ParticipantsLarry Wood - President, CEO...
Benzinga · Mar 6, 2026
Baird analyst David Rescott initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral rating and announces Price Target of $30.
SeekingAlpha · Mar 4, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRCT.
